A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
2020年6月25日 更新者：Mesoblast, Ltd.
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Study is a double-blind, randomized, placebo controlled, dose escalating study.
The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and who have had an incomplete response to at least one TNF-alpha inhibitor.
研究概览
研究类型
介入性
注册 (实际的)
48
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
New South Wales
-
Camperdown、New South Wales、澳大利亚、2050
- Royal Prince Alfred Hospital
-
-
Tasmania
-
Hobart、Tasmania、澳大利亚、7000
- Southern Clinical Research Pty Ltd
-
-
Victoria
-
Malvern、Victoria、澳大利亚、3145
- Emeritus Research
-
-
-
-
Alabama
-
Anniston、Alabama、美国、36207
- Pinnacle Research Group
-
-
Arizona
-
Gilbert、Arizona、美国、85234
- Arthrocare Arthritis Care and Research PC
-
-
California
-
El Cajon、California、美国、92020
- TriWest Research Associates
-
Los Angeles、California、美国、90025
- UCLA
-
Upland、California、美国、91786
- Inland Rheumatology Clinical Trials Incorporated
-
-
Florida
-
Ocala、Florida、美国、34474
- Ocala Rheumatology Research Center
-
Palm Harbor、Florida、美国、34684
- Arthritis Center
-
Sarasota、Florida、美国、34239
- Sarasota Arthritis Research Center
-
Tampa、Florida、美国、33614
- McIlwain Medical Group
-
-
Maryland
-
Baltimore、Maryland、美国、21224
- JHU Arthritis Center Baltimore
-
Frederick、Maryland、美国、21702
- Arthritis Treatment Center
-
-
Massachusetts
-
Worcester、Massachusetts、美国、01605
- Reliant Medical Group
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Clinic
-
-
New Jersey
-
Fair Lawn、New Jersey、美国、07410
- Office of Ramesh C. Gupta, MD
-
-
North Carolina
-
Charlotte、North Carolina、美国、28210
- DJL Clinical Research
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73102
- Health Research of Oklahoma
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15261
- University of Pittsburgh
-
-
Tennessee
-
Jackson、Tennessee、美国、38305
- West Tennessee Research Institute
-
-
Texas
-
Houston、Texas、美国、77034
- Accurate Clinical Research
-
San Antonio、Texas、美国、78217
- Texas Arthritis Research Center
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 80年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Males and Females ages 18-80 years old
- Active rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification criteria for the diagnosis of RA.
- Must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-CCP3) but without extra-articular disease or functional limitation
Patient with active RA defined as:
- ≥ 4 tender joint count (TJC) 28 joint count at screening and
- ≥ 4 swollen joint count (SJC) count 28 joint count at screening
- ESR ≥ 28 mm/hr or hsCRP >2.0 mg/L
- Patient has been taking MTX for at least 4 months with dose and route of administration stable for at least 8 weeks prior to screening
- Patient has had an inadequate response to at least one TNFα inhibitor with last dose at least 6 weeks prior to screening
- Use of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is permitted but must be stable for at least 3 months prior to screening
Exclusion Criteria:
- Pregnant women or women who are breastfeeding.
- Other investigational therapy received within 8 weeks or five half-lives (whichever is longer) prior to Screening (except as in exclusion #13).
- Known or suspected alcohol or drug abuse within three years preceding Screening.
- Autoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis)
- History of or current inflammatory joint disease other than RA (such as tophaceous gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis are excluded.
- Bedridden or confined to a wheelchair or patients with > 3 arthroplasties due to RA.
- History of diagnosed and/or treated malignancy with no evidence of recurrence in past 5 years
- Surgical procedures planned to occur during the trial (these patients may be rescreened following completion of and recovery from the surgical procedure).
- Use of TNFα inhibitor for treatment of RA at time of screening or within the 6 weeks prior to screening.
- Prior use of biologic agent for treatment of RA within 6 weeks prior to screening
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较：Normal Saline Placebo
Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
|
|
|
有源比较器：Allogeneic Mesenchymal Precursor Cells
Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion
大体时间：12 weeks post IV Infusion
|
To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 4 months and who have had an incomplete response to at least one course of a TNFα inhibitor. Overall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs and Chest x-ray. |
12 weeks post IV Infusion
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA
大体时间：12 weeks post IV infusion with MPCs
|
To assess the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to least one TNFα inhibitor.
|
12 weeks post IV infusion with MPCs
|
|
Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA
大体时间：52 weeks post IV Infusion
|
To evaluate the long-term efficacy and safety of allogeneic MPCs over the entire study duration in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to at least one TNFα inhibitor Safety will be assessed according to the following:
Efficacy will be assessed according to the following:
|
52 weeks post IV Infusion
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
合作者
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2013年7月1日
初级完成 (实际的)
2016年5月1日
研究完成 (实际的)
2017年3月1日
研究注册日期
首次提交
2013年4月19日
首先提交符合 QC 标准的
2013年5月9日
首次发布 (估计)
2013年5月10日
研究记录更新
最后更新发布 (实际的)
2020年6月26日
上次提交的符合 QC 标准的更新
2020年6月25日
最后验证
2020年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.